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Vasoactive peptideThe human endothelin receptors are members of the rhodopsin class A of G-protein coupled receptors and
key modulators of blood pressure regulation. Their functional in vitro characterization has widely been
limited by the availability of high quality samples. We have optimized cell-free expression protocols for the
human endothelin A and endothelin B receptors by implementing co-translational association approaches
of the synthesized proteins with supplied liposomes or nanodiscs. Efﬁciency of membrane association and
ligand binding properties of the receptors have systematically been studied in correlation to different mem-
brane environments and lipid types. Ligand binding was analyzed by a number of complementary assays
including radioassays, surface plasmon resonance and ﬂuorescence measurements. High afﬁnity binding of
the peptide ligand ET-1 to both endothelin receptors could be obtained with several conditions and the
highest Bmax values were measured in association with nanodiscs. We could further obtain the characteristic
differential binding pattern of the two endothelin receptors with a panel of selected agonists and antagonists.
Two intrinsic properties of the functionally folded endothelin B receptor, the proteolytic processing based on
conformational recognition as well as the formation of SDS-resistant complexes with the peptide ligand ET-1,
were observed with samples obtained from several cell-free expression conditions. High afﬁnity and speciﬁc
binding of ligands could furthermore be obtained with non-puriﬁed receptor samples in crude cell-free reac-
tion mixtures, thus providing new perspectives for fast in vitro screening applications.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
G-protein coupled receptors (GPCRs) are one of the most frequent
classes of membrane proteins encoded by the human genome and
they represent important drug targets [1,2]. The human endothelin
system comprises the two receptors endothelin A (ETA) and
endothelin B (ETB) which mediate the effect of the three naturaloline; BTE, brain total extract;
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l rights reserved.endothelin isopeptides ET-1, ET-2 and ET-3 [3]. Differential tissue
speciﬁc expression patterns of the two receptors regulate vasocon-
striction or vasodilatation [4]. The endothelin system is the main
modulator in cardiovascular regulation and dysfunctions can result
into pathological conditions like chronic heart failure or pulmonary
hypertension [5,6].
The biochemical characterization and development of drugs di-
rected against endothelin receptors are prerequisite for the clinical
treatment of several vascular disorders [7,8]. In vitro studies have so
far been problematic due to notorious difﬁculties in the preparative
scale production of high quality GPCR samples. By using continuous
exchange cell-free (CECF) expression systems, a number of intrinsic
problems common to the classical cell-based in vivo expression sys-
tems can be avoided [9,10]. CF expression is therefore one of the
most efﬁcient approaches for the overexpression of the human
endothelin receptors and probably also for other GPCRs [11–14]. We
previously showed the preparative scale CF expression of ETA and
ETB receptors either co- or post-translationally solubilized in deter-
gents [15–17]. However, interaction with the peptide ligand ET-1 re-
vealed signiﬁcant lower binding afﬁnities if compared with data from
the receptors in vivo [15].
CF expression is a relatively new technology and it allows the
modulation of GPCR sample quality by manifold variations of the
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precipitates (P-CF mode) followed by subsequent post-translational
solubilization in detergents. Alternatively, proteomicelles could be
produced co-translationally by supplementing appropriate detergents
directly into the CF reaction (D-CF mode). The solubilized GPCRs can
then be reconstituted into membranes by classical in vitro techniques.
The co-translational reconstitution could furthermore be attempted
by addition of lipids either as preformed liposomes or as nanodiscs
(NDs) into the CF reaction (L-CF mode). In particular interesting is
the combination of CF expression with the new ND technology
employing discoidal membrane structures of 10–20 nm in diameter
formed by a lipid bilayer core and surrounded by the membrane scaf-
fold protein (MSP) [17]. Considering the variety of potentially useful
detergents, lipids and other hydrophobic compounds, CF expression
represents currently the most variable production technique for
membrane proteins.
Lipids are known as frequent modulators of membrane protein
function. We have studied the ligand binding of the two CF expressed
endothelin receptors in different lipid environments with complemen-
tary techniques and by implementing post- as well as co-translational
reconstitution. The binding properties of a panel of agonists and antag-
onists to ETA and ETB have been studied. In addition, the characteristic
SDS-stable complex formation of ETB with the ET-1 ligand as well as its
conformation-speciﬁc proteolysis was analyzed.2. Materials and methods
2.1. Materials
Wild type ET-1, its biotinylated derivative Lys9-biotin-ET-1 (bET-1),
4-alanine(1,3,11,15)mutant ET-1 (4-Ala-ET-1) and biotin9-ET-3
(b-ET-3)were obtained from the Leibniz Institute forMolecular Pharma-
cology (FMP, Berlin, Germany); Radioactively labeled [125I]Tyr13-ET-1
(2200 Ci/mmol) was purchased from PerkinElmer (Rodgau-Jügesheim,
Germany). The ligands BQ-123 and IRL-1620 were purchased from
Tocris Bioscience (Bristol, United Kingdom).
The lipids L-α-phosphatidylcholine from soybean, Type IV-S
(Aso-PC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-
dimyristoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DMPG), 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC), 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine (POPC), heart total lipid extract, Escherichia coli
polar lipids, cholesteryl hemisuccinate and brain total extract were
purchased from Avanti Polar Lipids (Alabaster, USA).
Detergents used for resolubilization were 1-palmitoyl-2-hydroxy-
sn-glycero-3-[phospho-rac-(1-glycerol)] (LPPG) or 1-myristoyl-2-
hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] (LMPG) (Avanti
Polar Lipids, Alabaster, AL). In the D-CF mode, the detergents Brij78,
Brij35, digitonin (Sigma Aldrich, Taufkirchen, Germany) and Chaps
(Roth, Karlsruhe, Germany) were used.Table 1
Constructs and oligonucleotides.
Construct
(kDa)
Sequence Modiﬁcations
ETB
(47)
E27–S443 N-T7
C-His10
ΔETB
(43)
S65–S443 N-T7
C-His10
ETA
(48.7)
D20–N427 N-T7
C-His10
ETB-sGFP (74) E27–S443 N-T7
C-His10
ETA-sGFP
(75.7)
D20–N427 N-T7
C-His102.1.1. DNA techniques
DNA templates were constructed by standard PCR using the corre-
sponding oligonucleotide primers and Vent-DNA Polymerase (New
England Biolabs, Frankfurt, Germany) (Table 1). Puriﬁed DNA frag-
ments were cloned with BamHI and XhoI (New England Biolabs,
Frankfurt, Germany) into pET21a(+). For the construction of sGFP
fusions, PCR fragments of the sGFP coding region were cloned into
the XhoI restriction site of pET21a(+) vectors containing the coding
sequence for a poly(His)10 tag as well as for either ETA, ETB or
proteorhodopsin (PR).2.2. Cell-free expression
Basic CF expression protocols were previously described [18].
Bacterial S30 extracts were prepared from E. coli strain A19 and ana-
lytical scale reactions were performed in mini-CECF reactors [19].
Dialysis membranes with a cut-off of 12–14 kDa (Roth, Karlsruhe,
Germany) were used to separate the reaction mixture (RM) from the
feeding mixture (FM). The RM volume was 55 μl and the ratio RM/FM
was1:15. The reactionswere incubated for 16–20 h on a suitable shaker
at 30 °C. CF expressed proteins were collected either as a precipitate
(P-CF, L-CF + liposomes) or as supernatant (D-CF, L-CF + NDs) by
centrifugation at 18,000 ×g for 10 min at 4 °C.
P-CF precipitates were washed two times in buffer (20 mMTris–HCl,
pH 7.5 and 150 mM NaCl) and resuspended in buffer supplemented
with detergents in a volume equal to the corresponding RM. Protein sol-
ubilization was achieved by incubation with gentle shaking for 1 h at
30 °C. Residual precipitate was removed by centrifugation at 18,000 ×g
for 10 min. Detergents used for resolubilization were LPPG or LMPG.
In the D-CF mode, the detergent Brij78 at a ﬁnal concentration of 1%
was directly added into the RM.
Lipids for L-CF expression were Aso-PC, DMPC, DOPC, heart total
lipid extract and E. coli polar lipid mixture. The lipids were solubilized
in chloroform, evaporated under vacuum to a thin ﬁlm and complete-
ly dried overnight. The ﬁlm was resuspended in liposome buffer
(20 mM potassium phosphate, pH 7.0, 150 mM NaCl) to a ﬁnal con-
centration of 40 mg/ml, brieﬂy sonicated in a sonication bath and
extruded to a size of 0.2 μm. The formed liposomes were then directly
added into the RM to a ﬁnal concentration of 4 mg/ml. For the L-CF
mode in the presence of liposome/detergent mixtures, the detergents
Brij35 (0.04%), Brij78 (0.04%), digitonin (0.2%) and Chaps (0.5%) were
pre-mixedwith pre-formed Aso-PC liposomes and added directly into
the RM. For L-CF expression in the presence of NDs, pre-formed
NDs were directly added into the RM. MSP1D1 and MSP1E3D1 were
expressed in E. coli BL21 (DE3) cells and puriﬁed by Ni2+chelate afﬁn-
ity chromatography as described [17,20]. NDs were assembled with
DMPC, POPC, DMPG, Aso-PC, Aso-PC + 5% cholesterol hemisuccinate
and brain total extract. The lipids were solubilized in chloroform,
evaporated under vacuum and dried overnight. The lipid ﬁlm wasPrimer
F: CGG GGA TCC GAG GAG AGA GGC TTC CCG CCT GAC
R: CGG CTC GAG AGA TGA GCT GTA TTT ATT ACT GGA
F: CGG GGA TCG TTG GCA CCT GCG GAG GTG CCT AAA
R: CGG CTC GAG AGA TGA GCT GTA TTT ATT ACT GGA ACG
F: CGG GGA TCC ATG GAA ACC CTT TGC CTC AGG GCA
R: CGG CTC GAG GTT CAT GCT GTC CTT ATG GCT GCT
F: CGG CTC GAG CTA AAG GTG GAA GAA TTA TTC ACT TGG
R: CGG CTC GAG TTA TTT GTA CAA TTC ATC CAT ACC ATG
F: CGG CTC GAG CTA AAG GTG GAA GAA TTA TTC ACT TGG
R: CGG CTC GAG TTA TTT GTA CAA TTC ATC CAT ACC ATG
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Na-cholate) to a ﬁnal concentration of 50 mM. The lipids were
mixed with the puriﬁed MSPs in the presence of 0.1% DPC and incu-
bated for 15 min at room temperature. Removal of detergents and
formation of NDs were performed by dialysis for 24 h in buffer
(20 mM Tris–HCl, 100 mM NaCl).
2.3. Protein analysis
Protein samples supplemented with SDS loading buffer (7.5% SDS
(w/v), 50% (v/v) glycerol, 25% (v/v) β-mercaptoethanol, and 0.1%
(w/v) bromophenol blue in 0.3 M Tris–HCl pH 6.8) were analyzed
by SDS-PAGE. Samples were separated by 12% or 16% (w/v) SDS gels
and stained with Coomassie blue or analyzed by immunoblotting.
Gels were blotted on activated 0.45 μm immobilon-P membrane
(PVDF, Millipore, Eschborn, Germany) in wet Western blot apparatus
(MiniProtean IV, Bio-Rad, Munich, Germany). The membrane was
then blocked for 1 h in phosphate buffered saline supplemented
with 4% skim milk powder and 0.05% Tween-20 followed by incu-
bation with the ﬁrst antibody (anti C-terminal His-tag (dilution
1:2000); anti N-terminal T7-tag (dilution 1:2000) or anti-biotin per-
oxidase conjugate (1:1000)) at 4 °C overnight with gentle shaking in
antibody incubation buffer (phosphate buffered saline supplemented
with 1% skim milk powder and 0.05% Tween-20). For the anti
His-tag and anti T7-tag blots, after three washing steps in wash buffer
(phosphate buffered saline and 0.005% Tween-20), the secondary
antibody horse radish peroxidase conjugate was added in antibody
incubation buffer at a ﬁnal concentration of 1:5000 for 1 h at room
temperature. After extensive washing in washing buffer, the mem-
branes were analyzed by chemiluminescence in a Lumi-Imager F1
(Roche Applied Science, Mannheim, Germany). Protein concentra-
tions were routinely estimated by 280 nm absorption using Nanodrop
technology (Peqlab, Erlangen, Germany) and Lambert–Beer equa-
tions. For sGFP tagged proteins, samples were analyzed for ﬂuores-
cence using a Tecan Genios ﬂuorescence reader and concentrations
of protein samples were determined using a calibration curve.
Low temperature-SDS-PAGE: SDS resistant receptor/ligand com-
plexes were monitored by low temperature SDS-PAGE. ETB and
ΔETB receptors were D-CF (Brij78 1%) expressed and afﬁnity puriﬁed
by metal chelate chromatography (Brij35 0.1%). Protein aliquots
(0.5 μg to 2 μg) were incubated for 1 h at 4 °C with 10 ng of b-ET-1
in phosphate buffered saline in a total volume of 30 μl. Samples
were then mixed with SDS-PAGE loading buffer and separated on 16%
SDS-PAGE at 10 °C. The gels were blotted on PVDF membranes and
analyzed with anti-biotin peroxidase conjugate antibodies (Millipore,
Eschborn, Germany).
2.4. Protein puriﬁcation
After D-CF expression, the ﬁrst detergent Brij78 could be ex-
changed against a second detergent upon immobilized metal afﬁnity
chromatography. Samples were centrifuged at 18,000 ×g for 10 min
in order to remove precipitate. The supernatant was diluted 1:5 in
equilibration buffer (20 mM Tris–HCl, pH 7.5, 500 mM NaCl, 10 mM
imidazole and detergent at 5–10× critical micellar concentration
(CMC)) and mixed with pre-equilibrated NTA-agarose beads (Qiagen,
Hilden, Germany) loaded with Ni2+ ions. The mixture was incubated
overnight at 4 °C with gentle shaking and applied on an empty grav-
ity ﬂow column. The beads were washed with 10 column volumes
(CVs) of washing buffer 1 (20 mM Tris–HCl, pH 7.5, 500 mM NaCl,
30 mM imidazole and detergent at 5–10× CMC), 10 CVs of washing
buffer 2 (washing buffer 1 with 80 mM imidazole) and 10 CVs
of washing buffer 3 (20 mM Tris–HCl, pH 7.5, 150 mM NaCl and
detergent at 5–10× CMC). Proteins were ﬁnally eluted with elution
buffer (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 400 mM imidazole
and detergent at 5–10× CMC) in 4–5 fractions of 1 CV each.Immobilized metal afﬁnity chromatography was further applied to
purify co-translationally formed GPCR/ND complexes. In this case the
same buffers described previously were used but in the absence of any
detergent.
2.5. Reconstitution of liposomes
Reconstitution of proteoliposomes was done with P-CF produced
GPCR samples directly after resolubilization with 1% LMPG in lipo-
some buffer at a concentration of approx. 1.5 mg/ml. For D-CF
expressed samples, the detergent used for expression (Brij78 1%)
was exchanged against second detergents upon immobilized metal
afﬁnity chromatography. E. coli polar lipids or Aso-PC lipids were sol-
ubilized in 100% chloroform, evaporated under vacuum to a thin ﬁlm
and completely dried under vacuum overnight. After resuspension
of the lipidic ﬁlm in liposome buffer to a ﬁnal concentration of
20 mg/ml, the liposomes were extruded to a size of 0.2 μm. Protein
samples and liposomes were then mixed at different molar ratios
(from 1:250 to 1:4000). The mixture was incubated 1 h at room tem-
perature and the detergent removed by addition of 500 mg Biobeads
SM-2 (Bio-Rad, München, Germany) pre-equilibrated with liposome
buffer. After 1 h incubation, a new aliquot of Biobeads was added
and the sample incubated for up to 48 h at 18 °C. Proteoliposomes
were separated from empty liposomes in a discontinuous sucrose
gradient of 10–20–30–40% sucrose in liposome buffer by ultracentri-
fugation at 83,000 ×g (SW28 swing bucket rotor, Beckman Coulter,
Krefeld, Germany) for 16 h at 4 °C. The pelleted proteoliposomes
were resuspended in liposome buffer, shock frozen in liquid nitrogen
and stored at −80 °C.
2.6. Ligand afﬁnity chromatography
Avidin agarose beads (Pierce, Bonn, Germany) were prepared
following the manufacturer's recommendations and subsequently
incubated with 100 μg of b-ET-1 for each 100 μl of matrix. Peptide
loading was continued for 1 h at 4 °C in matrix buffer (20 mM Tris–
HCl, pH 7.5, 150 mM NaCl and 0.1% Brij35). Unbound ligand was
removed by washing with 3 CVs of matrix buffer. Puriﬁed ΔETB
(3 μM) in 0.1% Brij35 was diluted 1:3 in matrix buffer and loaded
on the matrix. The matrix was then incubated for 2 h at room temper-
ature with gentle shaking. The ﬂow through was collected and the
matrix was washed 10 times with 1 CV of matrix buffer in order to
remove unbound protein. Elution of the ligand bound receptor was
then performed using 2 mM D-desthiobiotin in matrix buffer. One
step of 0.5 CV was followed by 8 elution steps of 1 CV. Aliquots
of 32 μl (for the ﬂow through and the ﬁrst elution fraction) and of
55 μl (for the washing and elution fractions) were analyzed by 12%
SDS-PAGE followed by immunoblotting.
2.7. Ligand binding assays
For radioassays of proteoliposomes, 500 nM protein/well was incu-
bated with 500 pM [125I]Tyr13ET-1 (speciﬁc activity 2200 Ci/mmol)
(PerkinElmer, Rodgau-Jügesheim, Germany) in a ﬁnal volume of 50 μl
binding buffer (20 mM potassium phosphate, pH 7.0, 150 mM NaCl,
0.1% (w/v) bovine serum albumin) for 1 h at room temperature in
96-well microplates. In order to determine unspeciﬁc binding, the
samples were pre-incubated for 1 h at 4 °C with 4 μM ﬁnal concentra-
tion of unlabeled ET-1 before addition of labeled ligand. Reactions
were stopped by addition of cold binding buffer and samples were
transferred to GF/B glass ﬁber ﬁlters (Millipore, Eschborn, Germany)
pre-treated for 10 min with 0.3% polyethyleneimine and washed with
500 μl binding buffer. Unbound ligand was removed by washing
ﬁlters three times with 150 μl of binding buffer. Dry ﬁlters were ﬁnally
collected and the retained radioactivity was determined in a gamma
counter (Cobra II Auto gamma, PerkinElmer, Rodgau-Jügesheim,
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malian cell membrane preparations containing recombinant human
ETA or ETB receptor (Chemiscreen GPCR membrane preparation,
Millipore, Eschborn, Germany). Control membrane aliquots of 5 μg
were incubated with 500 pM of [125I]Tyr13ET-1 for 1 h at room tem-
perature. Unspeciﬁc binding was determined in the presence of
4 μM unlabeled ET-1.
For saturation radioassay experiments with NDs, 0.25 μl (7 ng) of
puriﬁed ETB-sGFP/NDs (DMPC) (30 μg/ml stock according to sGFP
ﬂuorescence), resulting into 5 nM estimated ﬁnal protein concentra-
tion per well was incubated with increasing concentrations of [125I]
Tyr13ET-1 in a ﬁnal volume of 20 μl in binding buffer (50 mM
Hepes, pH 7.5, 5 mM MgCl2, 1 mM CaCl2, 0.2% BSA) for 1 h at room
temperature. For competition experiments, same amounts of NDs
or proteoliposome samples were pre-incubated for 1 h at room tem-
perature with increasing concentrations of unlabeled ET-1 before
adjusting to 500 pM [125I]Tyr13ET-1. After 1 h incubation, the samples
were transferred to GF/B glass ﬁber ﬁlters pre-treated for 20 min with
0.3% polyethyleneimine and washed with 300 μl washing buffer
(50 mM Hepes, pH 7.5, 500 mM NaCl, 0.1% BSA). Unbound ligand
was removed by washing the ﬁlters ﬁve times with 150 μl washing
buffer. Radioactivity was ﬁnally measured with the dried ﬁlters.
Unspeciﬁc binding was determined in the presence of 2 μMunlabeled
ET-1.
For the determination of Cy3-ET-1 binding, 2 nM of immobilized
metal afﬁnity chromatography puriﬁed ETB-sGFP/ND (DMPC) or
PR-sGFP/ND (DMPC) (measured according the sGFP ﬂuorescence)
were incubated for 1 h with 10 nM Cy-3-ET-1 in a ﬁnal volume of
25 μl in binding buffer (phosphate buffer saline, pH 7.5). The mixture
was then applied on a Sephadex G50 spin column and centrifuged at
770 ×g for 2 min. The GPCR/ligand complex was collected in the
ﬂow-through while unbound ligand remained in the column. Fluores-
cence of Cy-3 was then measured using a Tecan Genios ﬂuorescence
plate reader (Excitation 535 nm, emission 612 nm) in order to deter-
mine the percentage of active receptor in a 1:1 binding model (RFU
measured in the ﬂow-through/511 RFU X 100, where 511 RFU are
the RFU measured for 2 nM Cy3-ET-1).
2.8. Confocal microscopy
Images were acquired using a Zeiss LS 510 confocal microscope
with an oil immersion Plan-Apochromat 63×/1.4. Excitation was pro-
vided by an argon lamp ﬁltered with standard bandpass excitation/
emission ﬁlter cubes.
2.9. Surface plasmon resonance (SPR)
Measurements were conducted with a Biacore X100 (Biacore,
Uppsala, Sweden) using SA chips. 50 resonance units (RUs) of
b-ET-1 or b-ET-3 were immobilized on chips. ETA, ETB and ETB deriv-
atives co-translationally associated with MSP1E3D1-NDs were either
metal afﬁnity puriﬁed or directly injected in the CF RMs without any
previous puriﬁcation. In single cycle kinetic experiments, concentra-
tion series of the analyte were injected without chip regeneration in
between the injections [21,22]. Kinetic parameters were analyzed
using a 1:1 interaction model. In multi cycle kinetic experiments,
the chips were regenerated with regeneration buffer (50 mM NaOH,
1 M NaCl) in between sample injections. Competition experiments
were performed using multi cycle kinetic experiments. Constant con-
centrations of GPCR/ND samples (5 nM ﬁnal protein concentration
according to sGFP ﬂuorescence) were incubated before injection
with increasing ligand concentrations from 0.01 nM to 6 μM for 1 h
at 4 °C. In all sensograms a report point at 10 s after the end of the
injection was placed and the RU measured at the report point were
plotted against the logarithm of the ligand concentration. Data wereanalyzed using GraphPad Prism 5 (GraphPad Software, San Diego,
CA) and processed by nonlinear regression curve ﬁtting.
3. Results
3.1. N-terminal processing and SDS resistant complex formation of CF
synthesized ETB with ET-1
The ETB receptor was either expressed by co-translational solubi-
lization in D-CF reactions supplemented with 1% Brij78, in P-CF reac-
tions with subsequent solubilization in 1% LMPG or in L-CF reactions
in the presence of MSP1E3D1-NDs (DMPC). ETA was D-CF synthe-
sized in the presence of 0.5% Brij35. In P-CF and D-CF modes, the
primary detergent of the samples was exchanged to 0.1% Brij35
upon metal afﬁnity chromatography. While a single ETB band corre-
sponding to a MW of approximately 40 kDa was detectable by
SDS-PAGE analysis from P-CF samples, two bands corresponding to
approximately 40 kDa and 35 kDa were observed with the D-CF and
L-CF samples (Fig. 1A). In contrast, only one band of approximately
41 kDa was detected after D-CF as well as after P-CF expression of
ETA (Fig. 1A). The formation of the ETB double band was found to
be independent from the selection of supplied detergents as well as
from the presence of 100 nM agonist ET-1. The sampleswere analyzed
afterWestern blotting by immunodetection with an anti-His antibody
and the detection of both bands of the D-CF samples indicated
the presence of intact C-terminal ends in the two ETB derivatives
(Fig. 1B). ETB further contains an N-terminal T7-tag and anti-T7-tag
antibodies reacted after Western blotting only with the larger
40 kDa band, indicating an N-terminal deletion of the 35 kDa ETB
derivative (Fig. 1B). A speciﬁc cleavage of the ﬁrst 64 amino acids of
ETB produced in HEK293 cells by putative metalloproteases has been
reported [23]. In order to analyze whether the origin of the second
band is based on a similar N-terminal cleavage, the mutant ΔETB
carrying a deletion of the ﬁrst 64 amino acids was prepared. The
D-CF expression of ΔETB resulted in a single band after SDS-PAGE
analysis apparently co-migrating with the lower 35 kDa band of
full-length ETB D-CF samples (Fig. 1A). Edman sequencing of the
35 kDa band indicated the residues alanine, proline and glutamic
acid in positions 3, 4 and 6, supporting the hypothesis of the speciﬁc
cleavage of ETB at amino acid position 64 (data not shown).
D-CF samples of ETB and ΔETB as well as D-CF produced samples
of ETA in Brij35 (0.1%) were incubated with the biotin labeled pep-
tide agonist b-ET-1 for 1 h. After separation by low temperature
SDS-PAGE, the samples were immunoblotted with anti-biotin anti-
bodies. A clear signal of b-ET-1 was detectable with both bands of
full-length ETB. The signal with the truncation ΔETB was weaker
but still detectable, while no bound ligand was observed with ETA
(Fig. 1B and C). The results gave evidence of SDS-resistant ETB/
b-ET-1 complexes, while putatively formed ETA/b-ET-1 complexes
were SDS sensitive. Aliquots of 13 nmol of the agonist b-ET-1 were
immobilized on monomeric avidin agarose columns and 0.67 nmol
of puriﬁed D-CF (1% Brij78) synthesized and into 0.1% Brij35 trans-
ferred ΔETB was loaded (Fig. 1D). After washing, the bound ΔETB/
b-ET-1 complexes were eluted with D-desthiobiotin and quantiﬁed
by immunoblotting with anti-His antibodies. A binding competence
of approximately 25% was measured for ΔETB which is comparable
to the previously determined efﬁciency of full-length ETB at similar
conditions [15].
3.2. ET-1 binding after post-translational reconstitution of ETB into
liposomes
Puriﬁed ETB samples after P-CF expression and solubilization in 1%
LMPG were in vitro reconstituted into liposomes composed out of
E. coli polar lipids or Aso-PC mixtures and analyzed for their binding
of radiolabeled [125I]Tyr13ET-1 in ﬁlter binding assays (Table 2).
Fig. 1. Analysis of CF expressed ETA and ETB. A, metal afﬁnity puriﬁed ETA and ETB derivatives after CF expression in P-CF, D-CF (1% Brij78) and L-CF (MSP1E3D1-ND DMPC) modes.
Separation by 12% SDS-PAGE and Coomassie-blue staining. B, immunoblot of D-CF (1% Brij78) produced ETB and ETA. Sample volumes of 1 μl were separated by 12% SDS-PAGE and
immunoblotted with anti-His or anti-T7 antibodies. For immunodetection with anti-biotin antibodies, 1 μl samples were ﬁrst incubated for 1 h at 4 °C with 100 nM of b-ET-1 in
phosphate buffered saline, separated by 12% SDS-PAGE at 10 °C and then blotted. C, formation of SDS-resistant ET-1 complexes with D-CF produced ETB and ΔETB. Different con-
centrations of puriﬁed protein samples were incubated with 100 nM b-ET-1 in phosphate buffered saline for 1 h at 4 °C. Samples were then separated by 16% SDS-PAGE at 10 °C
and immunoblotted with anti-biotin antibodies. D, ligand afﬁnity chromatography of D-CF produced ΔETB. 1 μM puriﬁed receptor in 0.1% Brij35 was incubated with 100 μg of
b-ET-1 immobilized on monomeric avidin agarose matrix, washed and eluted with 2 mM D-desthiobiotin. Samples of all fractions were separated by 16% SDS-PAGE and
immunoblotted with anti-His-tag antibodies. M, marker; FT, ﬂow-through fraction; W, wash fractions; E, elution fractions.
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determined after blocking of speciﬁc binding sites by preincubation
with an excess of 4 μM non-labeled ET-1. The results indicate that
the functional reconstitution of P-CF synthesized ETB strongly de-
pends on the ratio of protein to lipid. The highest speciﬁc [125I]
Tyr13ET-1 binding of 49% with a Bmax of 2.1 pmol/mg was obtainedTable 2
125I-ET-1 binding to ETB.
Mode 1st detergenta 2nd detergentb Lipidsc P
P-CF LMPG, 1% – EPL 1
EPL 1
EPL 1
EPL 1
EPL 1
Aso-PC 1
D-CF Brij78, 1% LPPG (0.05%) EPL 1
LMPG (0.05%) EPL 1
DPC (0.1%) EPL 1
DPC (0.1%) EPL 1
DDM (0.05%) EPL 1
Chaps (1%) EPL 1
Brij78 (0.1%) EPL 1
L-CF Brij35, 0.04% – Aso-PC 4
Brij78, 0.04%
Digitonin, 0.2%
Chaps, 0.5%
– – EPL
HTL
DOPC
DMPC
Aso-PC
– – ND 4
Positive CTR (Chemiscreen ETA membrane preparation)
Positive CTR (Chemiscreen ETB membrane preparation)
a Detergent used for resolubilization of P-CF generated pellets or as supplement for D-CF
b Detergent used for elution upon metal afﬁnity puriﬁcation.
c EPL: E. coli polar lipids; HTL: heart total lipid extract; ND: MSP1E3D1-NDs (DMPC).
d Percentage of the speciﬁc binding on the total binding.
e Final concentration in the RM.with EPL in a protein to lipid ratio of 1 to 1000 and in homologous
competition experiments with the same sample a Ki of 2.1 μM was
measured (Table 2).
D-CF (1% Brij78) synthesized ETB samples were transferred into a
variety of different secondary detergents and reconstituted into E. coli
polar lipids at a protein to lipid ratio of 1 to 1000 or 1 to 2000. In all/L-ratio Speciﬁc bindingd
(%)
Speciﬁc activity
(pmol/mg)
KD
(nM)
:250 32 ± 2 2 ± 0.2 –
:500 26 ± 1 1.2 ± 0.1 –
:1000 49 ± 3.5 2.1 ± 0.3 2100 (Ki)
:2000 26 ± 1 0.8 ± 0.03 –
:4000 15 ± 3.5 0.3 ± 0.1 –
:1000 36 ± 2 1.7 ± 0.1 –
:1000 7 ± 3 0.1 ± 0.01 –
:1000 30 ± 5 0.4 ± 0.02 –
:1000 34 ± 6 0.46 ± 0.2 –
:2000 26 ± 7 0.37 ± 0.1 –
:1000 7 ± 2 0.08 ± 0.02 –
:2000 14 ± 2.5 0.16 ± 0.03 –
:1000 6 ± 3 0.05 ± 0.02 –
mg/mle 38 ± 1 3.3 ± 0.1 –
39 ± 2 1.5 ± 0.15 –
25 ± 1 1.3 ± 0.1 –
25 ± 8 1.6 ± 0.4 –
31 ± 3 2.6 ± 0.3 –
27 ± 4 1.1 ± 0.2 –
21 ± 3 1.2 ± 0.08 –
32 ± 1 1.6 ± 0.2 –
36 ± 2 3.5 ± 0.3 1300 (Ki)
0 μM5 67.5 ± 1.5 31.6 ± 0.5 0.45
87.5 ± 3 1.4 ± 0.2 0.09
85 ± 2 0.5 ± 0.05 0.06
or L-CF expression.
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higher than 50% was detected and best values of approximately 34%
speciﬁc binding were obtained with ETB samples in 0.1% DPC as
secondary detergent, but at a relatively low Bmax of 0.46 pmol/mg
(Table 2). In contrast, commercial positive control membrane frac-
tions containing overexpressed human ETA or ETB receptor showed
a high speciﬁc [125I]Tyr13ET-1 binding of approximately 87.5% and
85%, respectively, while the Bmax values were also in the range of
approximately 1 pmol/mg (Table 2).
3.3. ET-1 binding after co-translational association of ETB with liposomes
Contact with detergent could impair the functional folding of CF
expressed ETB and as alternative strategy, the detergent-free
co-translational reconstitution of ETB into supplied preformed lipo-
somes was analyzed in the L-CF expression mode. For faster optimiz-
ing and monitoring, an ETB-sGFP fusion construct was used. P-CF
expressed ETB-sGFP completely precipitates into a non-ﬂuorescent
pellet. The detection of folded and ﬂuorescent sGFP could therefore
serve as preliminary indicator for the association of synthesized
ETB-sGFP with the provided liposomes. Preformed liposomes com-
posed out of different lipids were supplied into the CF reaction at a
ﬁnal concentration of 4 mg/ml and the sGFP ﬂuorescence was mea-
sured after the expression reaction (Fig. 2). Fluorescence of sGFP
was only detected in the precipitate, indicating the co-precipitation
of the supplied lipids with associated ETB-sGFP. Analysis of a rep-
resentative L-CF (Aso-PC) precipitate sample by ﬂuorescence mi-
croscopy revealed large heterogeneous liposomes in size ranges
in between 5 and 20 μm (Fig. 4A). Fluorescent ETB-sGFP particles
were only detected in association with the liposomes, indicating a
positive effect of the lipids on the folding of at least the sGFP fusion
partner.
Comparable ﬂuorescence intensities corresponding to a calcu-
lated total of approximately 40 μg of ETB-sGFP per ml RM were
determined after addition of liposomes composed out of Aso-PC,
E. coli polar lipids or DOPC. The addition of liposomes composed out
of heart total lipid extract or DMPC yielded only approximately
10 μg/ml of ﬂuorescent ETB-sGFP. The initial mixing of supplied lipids
with 0.5% Chaps followed by subsequent dilution of the detergent into
the FM during the expression reaction reduced the formation of ﬂuo-
rescent ETB-sGFP.
The binding of [125I]Tyr13ET-1 to selected L-CF produced samples
was analyzed by ﬁlter binding assays. The non-speciﬁc background
binding of [125I]Tyr13ET-1 was again very high and the best speciﬁc
binding within the range of 31–36% was obtained with liposomesFig. 2. L-CF expression screening of ETB-sGFP. Co-translational association of ETB-sGFP
with different liposomes. Fluorescence values were normalized according to the
maximum expression (40 μg/ml of ETB-sGFP with Aso-PC liposomes). Values for L-CF
and L/D-CF with initial presence of 0.5% CHAPS in the RM are given.composed out of Aso-PC or E. coli polar lipids at Bmax values of
3.5 pmol/mg and 2.6 pmol/mg, respectively (Table 2). In homologous
competition experiments using proteoliposomes composed out of
Asp-PC lipids a Ki of 1.3 μM was measured (Table 2). L-CF generated
complexes of the control protein PR-sGFP with supplied E. coli polar
lipid liposomes showed approximately 27% of [125I]Tyr13ET-1 signal
over the background, but at a low Bmax of only 0.02 pmol/mg
(Fig. 3).
3.4. Co-translational formation of ETB/ND and ETA/ND complexes
Prepared NDs (DMPC) of two size ranges by using either MSP1D1
or MSP1E3D1 were supplied into the CF reaction. For the initial
optimization of the integration/association efﬁciency, the ETB-sGFP
fusion was used and ﬂuorescence in supernatant and pellet was
quantiﬁed after the expression reactions (Fig. 5A). The amount of sol-
uble sGFP ﬂuorescence increased with increasing concentrations of
MSP1E3D1-NDs in the RM and reached a plateau at concentrations
in between 60 and 180 μM (Fig. 5A). According to the sGFP ﬂuores-
cence, approximately 150 μg/ml of ETB-sGFP protein was synthesized
having at least a functionally folded sGFP moiety. A MSP1E3D1-ND
concentration of approximately 40 μMwas already sufﬁcient to obtain
all detectable ﬂuorescence in the supernatant. With the smaller
MSP1D1-NDs, approximately 25% of the ﬂuorescent ETB-sGFP still
remained in the pellet at ND concentrations of 40 μM. Fluorescence
microscopy revealed larger clusters of NDs in the pellets together with
associated ETB-sGFP protein (Fig. 4B). The MSP1E3D1-NDs in the su-
pernatant had a higher apparent homogeneity while the presence of
smaller cluster can still not be excluded (Fig. 4B).
The membrane composition of MSP1E3D1-NDs was modiﬁed and
all prepared NDs were supplied into CF reactions at a ﬁnal concentra-
tion of 40 μM. The obtained ETB-sGFP ﬂuorescence was quantiﬁed in
the supernatants as well as in the pellets. NDs with membranes com-
posed out of the anionic lipid DMPG increased the yield of ﬂuorescent
ETB-sGFP to a level twice as high if compared with NDs (DMPC)
(Fig. 5B). NDs containing membranes composed out of all other ana-
lyzed lipids such as POPC, lipids isolated from brain total extracts
or Aso-PC mixtures reduced the yield of ﬂuorescent ETB-sGFP if
compared with NDs (DMPC). A large fraction of the complexes ofFig. 3. Radioligand binding of CF produced ETB samples post- (P-CF, D-CF) or
co-translationally (L-CF) associated with liposomes. Samples were incubated with
500 pM [125I]-ET-1 for 1 h and then assayed. In competition experiments, the samples
were pre-incubated with an excess of 4 μM unlabeled ET-1. Values were normalized
according to the maximum count (ETB L-CF ± 35,000 CPM). ETB P-CF: resolubilized
in 1% LMPG and reconstituted 1 to 1000 in EPL; ETB D-CF: expression in the presence
of 1% Brij78, detergent exchange to 0.1% DPC and reconstitution 1 to 1000 in EPL; ETB
L-CF: expression in the presence of 4 mg/ml Aso-PC; ETB L/D-CF: expression in the
presence of 0.04% Brij78 and 4 mg/ml Aso-PC; PR L-CF: expression in presence of
4 mg/ml Aso-PC.
Fig. 4. Fluorescence microscopy of L-CF expressed ETB-sGFP samples. A, precipitate of L-CF expressed ETB-sGFP with Aso-PC liposomes. Green, ETB-sGFP; red, Aso-PC labeled with
rhodamine. B, L-CF expression of ETB-sGFP with MSP1E3D1-NDs (DMPC). Left: pellet; right: supernatant.
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the CF reactions, while complexes with NDs containing any of the
other analyzed lipids quantitatively stayed in the supernatant.
A corresponding screening was performed for the expression opti-
mization of ETA-sGFP (Fig. 5B). At 40 μMMSP1D1-NDs (DMPC) most
of the ﬂuorescent protein fraction was recovered in the pellet. With
the larger MSP1E3D1-NDs, approximately 25 μg/ml of ﬂuorescent
ETA-sGFP could be obtained in the supernatant. Similar to ETB-sGFP,
with NDs (DMPG) the ﬂuorescence yield of ETA-sGFP was twice if
compared to expression experiments with NDs (DMPC) (Fig. 5B).
3.5. Binding of Cy3-ET-1 to ETB-sGFP/ND complexes
In order to evaluate the ligand binding ability of the produced
ETB-sGFP/MSP1E3D1-NDs (DMPC), a binding experiment using the
ﬂuorescent ET-1 analog Cy3-ET-1 was performed. ND samples were
puriﬁed by metal afﬁnity chromatography and 2 nM of protein
(according to sGFP ﬂuorescence) was incubated with 10 nM of
Cy3-ET-1 for 1 h at room temperature. Free ligand was then removed
with Sephadex G50 spin columns and the amount of ligand binding
active receptor in the ETB-sGFP/ND (DMPC) sample correspondedFig. 5. L-CF (ND) expression optimization of ETB-sGFP and ETA-sGFP. A, L-CF expression in
supernatant or pellet were analyzed for sGFP ﬂuorescence and protein was quantiﬁed acc
assembled with membranes of different lipid compositions. Complex formation was anal
ETB-sGFP complex formation with MSP1E3D1-NDs (DMPC).to 24 ± 3% according to the measured Cy3-ET-1 ﬂuorescence. Ap-
proximately 75% of the Cy3-ET-1 binding could be blocked by pre-
incubation of the receptor sample with 2 μM unlabeled ET-1 for
1 h at room temperature. The total Cy3-ET-1 binding of PR-sGFP/
MSP1E3D1-NDs (DMPC) or empty MSP1E3D1-ND (DMPC) controls
was less than 1.5% (Fig. 6).
3.6. Differential binding of ETA/ND and ETB/ND complexes to the natural
agonists ET-1 and ET-3
The ligand binding of ETB-sGFP/MSP1E3D1-ND (DMPC) complexes
was analyzed in saturation assays using [125I]Tyr13ET-1. Experiments
were performed with metal afﬁnity puriﬁed complexes at a ﬁnal
concentration of 5 nM as estimated by sGFP ﬂuorescence. A KD of
0.45 nM and a Bmax of 58.6 pmol/mg were determined (Fig. 7A).
Competition experiments with 5 nM of ETB-sGFP/ND complexes pre-
incubated for 1 h at RT with increasing concentrations of unlabeled
ET-1 and subsequent addition of 500 pM of [125I]Tyr13ET-1 revealed a
Ki of 6.1 nM (Fig. 7B).
ETB-sGFP/MSP1E3D1-ND (DMPC) complexes are highly soluble and
therefore SPR measurements could be performed as complementarythe presence of MSP1D1-NDs (DMPC) or MSP1E3D1-NDs (DMPC). Aliquots of 3 μl of
ording to a calibration curve. B, ETB-sGFP and ETA-sGFP complex formation with NDs
yzed at a ﬁnal ND concentration of 40 μM. Values were normalized according to the
Fig. 6. Cy-3-ET-1 binding to ETB-sGFP/MSP1E3D1-ND (DMPC) complexes. 2 nM of metal
afﬁnity puriﬁed ETB-sGFP/MSP1E3D1-NDs (DMPC) or PR-sGFP/MSP1E3D1-ND (DMPC)
complexes (quantiﬁed by sGFP ﬂuorescence) was incubated with 10 nM Cy-3-ET-1.
Unbound ligandwas removed by Sephadex G50 spin columns and the amount of ﬂuores-
cent ligand eluted in the ﬂow-through together with the protein/ND complexes was
measured.
Table 3
Apparent KD values determined with GPCR derivatives in MSP1E3D1-NDs of different
lipid compositions and analyzed by SPR measurements or by radioassays.
Lipid Ligand ETB-sGFP ETB-sGFP
(pure)
ETB ΔETB ETA-sGFP
DMPC b-ET-3 0.2 – – – 3400
DMPC b-ET-1 0.5 0.4 0.5 0.6 1.7
DMPC [125I]Tyr13ET-1 0.45 – – – –
PC b-ET-1 0.69 – – – –
PC + 5% CHS b-ET-1 0.47 – – – –
POPC b-ET-1 0.73 – – – –
BTE b-ET-1 0.53 – – – –
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samples. Amounts of 50 RUs of the ETA/ETB speciﬁc ligand b-ET-1 or
of the ETB speciﬁc ligand b-ET-3 were immobilized on SA biosensor
chips and the binding characteristics of ETA, ETB and the corresponding
GPCR-sGFP fusions co-translationally associated with MSP1E3D1-NDs
were determined. Supernatants from L-CF reactions containing
ETB-sGFP or ETA-sGFP complexes with MSP1E3D1-NDs (DMPC) were
directly analyzed without any previous puriﬁcation. For non-puriﬁed
ETB-sGFP, an apparent KD value for the interaction with b-ET-1 of
0.5 nMwas obtained (Table 3). The apparent KD value of IMAC puriﬁed
ETB-sGFP/MSP1E3D1-ND (DMPC) complexes was similar and deter-
mined at 0.4 nM. Accordingly, the non-fused ETB and the truncated
derivative ΔETB showed similar KD values of 0.5 nM and 0.6 nM,
respectively. For reaction supernatants containing non-puriﬁed ETA-
sGFP/MSP1E3D1-ND (DMPC) complexes, an apparent KD value for
the interaction with ET-1 of approximately 1.7 nM was determined.
However, the KD values of corresponding GPCR samples were clearly
different for their interaction with the peptide b-ET-3. ETB-sGFP
still showed high afﬁnity with an apparent KD of 0.2 nM, whereas theFig. 7. Radioligand binding assay of ETB-sGFP/MSP1E3D1-ND (DMPC) complexes. A, satura
with increasing concentrations of [125I]Tyr13ET-1. Unspeciﬁc binding was determined in
5 nM of puriﬁed ETB-sGFP/MSP1E3D1-NDs (DMPC) was incubated with increasing concentr
surements of two independent experiments.apparent KD value for ETA-sGFP was with 3.4 μM signiﬁcantly higher,
indicating low afﬁnity (Table 3).
The effect of the membrane composition on the ligand binding
activity of ETB-sGFP complexed with MSP1E3D1-NDs was further
analyzed (Table 3). ETB-sGFP was expressed in the presence of NDs
of different lipid compositions and the resulting ETB-sGFP/ND com-
plexes were metal afﬁnity puriﬁed. In ND complexes with mem-
branes composed out of either Aso-PC or POPC a similar strong
afﬁnity of ETB-sGFP to b-ET-1 with apparent KD values of approxi-
mately 0.7 nM was obtained. The apparent KD values became slightly
decreased to approximately 0.5 nM if cholesterol hemisuccinate was
added into Aso-PC membranes or when brain total extract lipid mix-
tures were used. Unfortunately, despite the relatively high ﬂuores-
cence of ETB-sGFP in DMPG membranes, the ligand binding could
not further be analyzed due to strong interactions of b-ET-1 with
the anionic lipid.
3.7. Differential binding of ETA-sGFP/ND and ETB-sGFP/ND complexes to
artiﬁcial agonists and antagonists
A panel of ligands comprising modiﬁcations of the natural ET-1
agonist as well as artiﬁcial non-peptide antagonists that show distinct
differential binding patterns to ETA and ETB is known. While the pep-
tide agonist ET-1 is non-selective for both receptors, the two peptide
derivatives ALA-4-ET-1 and IRL-1620 are highly speciﬁc agonists for
ETB with more than 1000 fold reduced binding to ETA. Vice versa,
the antagonist BQ-123 is highly selective for ETA.
The interaction of these ligands with ETA-sGFP and ETB-sGFP
in complexes with MSP1E3D1-NDs (DMPC) was analyzed in b-ET-1
competition binding assays using SPR (Fig. 8A and B). Fixed concentra-
tions (5 nM) of ETA-sGFP/NDs or ETB-sGFP/NDs were preincubated
with increasing concentration of ligands in the range from 0.01 nM
to 6 μM for 1 h and injected on SA chips containing immobilized
b-ET-1 ligand. For ETB-sGFP/ND complexes, the determined IC50
values were 9.6 nM for ET-1, 4.1 nM for ALA-4-ET-1, 0.005 nM fortion binding assay. 5 nM of puriﬁed ETB-sGFP/MSP1E3D1-NDs (DMPC) was incubated
the presence of 2 μM unlabeled ET-1 and subtracted. B, competition binding assay.
ations of unlabeled ET-1 in the presence of 500 pM [125I]Tyr13ET-1. Data are triple mea-
Fig. 8. Differential ligand binding of ETA-sGFP and ETB-sGFPMSP1E3D1-ND (DMPC) complexes. 50 RUs of b-ET-1 were immobilized on SA chips. A, ETA-sGFP; B, ETB-sGFP. Apparent
IC50 values were determined in competition assays with 5 nM of complex pre-incubated with increasing concentrations (1 pM to 20 μM) of ET-1, 4-Ala-ET-1, BQ-123 or IRL-1620 1 h
before injection. Report points at 10 s after injection were plotted against the logarithms of the corresponding ligand concentrations. Data were analyzed with non-linear regression
curve ﬁtting using GraphPad Prism 5. The measured apparent values are summarized below the ﬁgure.
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For ETA-sGFP/ND complexes, the IC50 value for the cognate ligand
ET-1 was 8 nM and for the speciﬁc antagonist BQ-123 38 nM. The
IC50 values for the ETB speciﬁc agonists ALA-4-ET-1 and IRL-1620
were 2.6 μM and 300 nM, respectively (Fig. 8A).
4. Discussion
Functionally folded ETB receptor shows a number of intrinsic
characteristics. The N-terminal domain is in vivo subject to proteolytic
cleavage in between the amino acid residues R64 and S65 [23,24]. The
cleavage is catalyzed by a yet unidentiﬁedmetalloprotease and recog-
nition is based on receptor conformation rather than on the primary
sequence of the cleavage site [24]. Efﬁciency of the in vivo cleavage
and its physiological relevance is still not fully analyzed. The afﬁnities
of ETB and ΔETB to the ET-1 peptide are similar in vivo which is in
accordance with our results with the CF expressed proteins. However,
ΔETB is not able to induce EGF receptor transactivation, indicating
differences in the functionality of the two forms [23]. The N-terminal
cleavage of the ETB domain was only detectable upon soluble expres-
sion in the D-CF and L-CF (MSP1E3D1-ND (DMPC)) modes. The pre-
cipitation of ETB in the P-CF mode therefore either restricts access
to the proteolytic site or it alters the receptor conformation thus
preventing recognition by the protease. Conformational selection
mechanisms by recognition of three-dimensional structural motifs
are known from other metalloproteases like the collagenase super-
family or from the amyloid precursor protein cleaved by α-secretase
[25]. The processing during soluble CF expression gives evidences
that ETB adopts a native-like conformation resulting into the con-
formational recognition by an endogenous protease in the E. coli
S30 extract with a similar speciﬁcity as the yet unidentiﬁed human
protease.
A further speciﬁc property of ETB, again not shared with ETA, is
the formation of highly stable and even SDS resistant complexes
with ET-1 [26–28]. CF produced samples of ETB and ΔETB showed
persistent complexes with b-ET-1 after low-temperature-SDS-PAGE,
while in contrast b-ET-1 complexes with ETA were SDS sensitive.
The physiological relevance of this feature could be the potential
role of ETB to rapidly clear ET-1 from the vascular system after signal
induction.
Lipid association efﬁciencies and ligand binding characteristics of
ETB were analyzed after post- as well as after co-translational recon-
stitution approaches. Similar [125I]Tyr13ET-1 binding was determined
with proteoliposomes obtained either after post-translational recon-
stitution with P-CF synthesized ETB or after co-translational reconsti-
tution in the detergent-free L-CF mode. [125I]Tyr13ET-1 bindingefﬁciencies with proteoliposomes obtained with D-CF expressed ETB
samples were generally lower despite signiﬁcant variations depen-
dent on the selected detergents could be observed. ETB samples
obtained after D-CF expression in the presence of Brij78 are more
homogenous and have a higher ET-1 binding competence if compared
with samples obtained after P-CF expression [12]. The increased func-
tional reconstitution of P-CF samples could therefore give evidence of
an improved lipid association of partially unfolded proteins accompa-
nied by subsequent folding. The ETB-sGFP proteoliposomes produced
by co-translational reconstitution in the L-CF mode almost quantita-
tively precipitated during the reaction, presumably due to rearrange-
ments and fusions of the supplied liposomes upon association with
the newly synthesized proteins [29–31]. A special reaction modiﬁca-
tion by forming liposomes upon slow reduction of initial detergent
concentrations in the reaction mixture did not improve this effect
[32]. The detection of ﬂuorescent ETB-sGFP exclusively in association
with liposomes further supports the evidence of functional reconsti-
tution and indicates sGFP as useful fusion partner for the initial
screening of functional GPCR expression in CF systems.
Speciﬁc activities in [125I]Tyr13ET-1 binding comparable to com-
mercial mammalian membranes containing overexpressed ETB were
obtained with ETB proteoliposomes produced by a number of CF
expression conditions. However, a clear difference was the generally
higher unspeciﬁc background binding of [125I]Tyr13ET-1 to CF pro-
duced proteoliposomes. Speciﬁc [125I]Tyr13ET-1 binding was mostly
in between 25% and 40%, while the control membranes containing
overexpressed ETA or ETB reached levels of approximately 85% of
speciﬁc [125I]Tyr13ET-1 binding. We speculate that tight lipid associa-
tion of only partially folded ETB receptor that still retain some resid-
ual ligand binding competence might account for the observed high
background binding of [125I]Tyr13ET-1. This effect could also result
into the relatively high Ki values of ET-1 within the μM range ob-
served in [125I]Tyr13ET-1 competition assays with proteoliposome
samples obtained after post-translational reconstitution of P-CF syn-
thesized ETA or ETB as well as after co-translational L-CF expression
of ETB [15].
The post-translational assembly of NDs with puriﬁed GPCRs or
other membrane proteins is a new and rapidly evolving approach
and becomes most promising for the preparation of homogenous pro-
tein samples in lipid environments [33–38]. An interesting emerging
modiﬁcation of this process is the co-translational association of
membrane proteins with NDs by CF expression as it avoids any con-
tact of the membrane protein with detergents [20,39–42]. Detergent
sensitive membrane proteins such as the E. coli MraY translocase
could be synthesized by this strategy in stable and functionally folded
conformation [20]. The co-translational formation of ligand binding
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Neurokinin 1 Receptor (NK1R), the Dopamine D1 Receptor (DRD1)
and the β2-adrenergic receptor [43] as well as with derivative of the
β2-adrenergic receptor having the third intracellular loop replaced
by T4 lysozyme [41]. We could show for the ﬁrst time the production
of ligand binding active ND complexes with the two endothelin recep-
tors having their native full-length amino acid sequence.
The larger MSP1E3D1-NDs were clearly more efﬁcient for ETA and
ETB association and this is in accordance to previous ﬁndings with the
L-CF (ND) expression of other larger polytopic membrane proteins
[20]. Compared to the L-CF expression mode in the presence of
liposomes, three to four times more ﬂuorescent ETB-sGFP could be
obtained by using NDs. The stable and more homogenous dispersion
of the NDs as well as the membrane accessibility from both sides
might therefore support the association of folded ETB-sGFP protein.
However, membrane association or insertion mechanisms in this arti-
ﬁcial system are still largely unclear. ETB-sGFP as well as ETA-sGFP
are both expressed at similar levels and without any signal sequence.
Nevertheless, the formation of ﬂuorescent ETB-sGFP was approx.
twice as high as with ETA-sGFP in the presence of equal concentra-
tions of MSP1E3D1-NDs (DMPC). The two receptors show roughly
63% amino acid homology with conserved transmembrane segments
and higher degrees of variation within the extracellular regions
[44]. One striking difference is the presence of a mainly hydrophilic
region in the N-terminal domain of ETA (His66-Ser77), compared to
a hydrophobic region in ETB (Pro87-Glu98). A further hydrophilic
stretch is found in the ﬁrst extracellular loop of ETA (Asp149-Phe153).
These structural differences, which are suspected to play a role in the
differential ligand binding properties [45,46], may also modulate their
association with NDs.
The lipid composition determines thickness, ﬂuidity and surface
charge of the membrane and can therefore strongly modulate the
association of membrane proteins with NDs as well as their enzymatic
activity [20]. The ﬂuorescence yields of ETB-sGFP were twice as high
with NDs (DMPG) if compared with NDs (DMPC). The anionic lipid
DMPG was also shown to be most effective in the co-translational
formation of ND complexes with functionally folded MraY protein
[29] as well as for the post-translational insertion of bacteriorhodop-
sin into NDs [37]. Unfortunately, high interaction of peptide ligands
with the DMPG membranes prevented so far more detailed analysis
of ETB binding characteristics in this environment and DMPC as one
of the most prevalent eukaryotic lipids was selected as environment.
The binding of ET-1 to ETB-sGFP/MSP1E3D1-NDs appeared to be
relatively independent from the selected lipid environments. Accord-
ingly, also the ligand binding of the neurotensin-1 receptor in ND
complexes was found to be unaffected by the lipid composition,
whereas Gq protein coupling was correlated to the POPG content
[37]. In addition, the interaction of arrestin with rhodopsin/ND
complexes was modulated by acidic lipid head groups [47]. Effects of
lipid composition on signal transduction or extended differential
ligand bind of the endothelin receptors can therefore currently not
be excluded and will be subject of further investigation.
Ligand binding assays using the ﬂuorescent analog Cy3-ET-1 and
metal afﬁnity puriﬁed ETB-sGFP/MSP1E3D1-ND (DMPC) complexes
revealed approx. 20% of active receptor. Further estimations are pos-
sible from the radioligand binding assays. If Bmax values obtained
with the control membranes (approx. 4200 CPM/μg) are compared
with those obtained with ETB-sGFP/MSP1E3D1-ND (DMPC) samples
(approx. 1200 CPM/μg), approx. 28% active receptor can be calculated.
Alternatively, if one binding site per ETB-sGFP (MW = 74,000 Da) is
assumed, approx. 650 ng active receptor per total yield of 150 μg/ml
can be calculated from the binding kinetics. The speciﬁc activity of
58.6 pmol/mg with ETB-sGFP/MSP1E3D1-ND (DMPC) complexes is
higher if compared with membrane fractions of ETB overexpressing
CHO cells (0.5 pmol/mg), while total amounts are similar to those
obtained from COS cells (60 pmol/mg) [26]. SF9 cells appear to bemore productive with 100 pmol/mg (15–20 nmol/L) for ETB, whereas
other GPCRs such as the β-adrenergic or muscarinic receptors are
expressed in SF9 cells at similar concentrations in between 5 and
30 pmol/mg [48].
NDs allow the analysis of associated membrane proteins by tech-
niques established for soluble proteins such as SPR measurements
[22,49–51]. Our report is one of the ﬁrst examples of SPR analysis of
GPCR/ND complexes. The sGFP fusions of ETA and ETB were shown
to be useful for protocol development and did not affect ligand
binding as control experiments with non-fused receptors gave similar
afﬁnities to b-ET-1 and comparable to expected values from the liter-
ature [52]. The differential ligand binding of the endothelin receptors
in vivo is well characterized and the two physiological relevant
ligands ET-1 and ET-2 have comparable high afﬁnities of 0.1–0.8 nM
for both proteins [53,54]. The determined afﬁnity of b-ET-1 to the
CF expressed ETA/ND and ETB/ND complexes matches nicely with
the expected values. Again in accordance with the literature, the
expected KD value of b-ET-3 is in the same low range for ETB, but
>2 μM for ETA. The IC50 values analyzed in ET-1 binding competition
with cellular membranes containing ETB are 0.3 nM for ALA-4-ET-1,
0.1–50 nM for IRL-1620 and >1.5 μM for BQ-123. The corresponding
values with membranes containing ETA are >2 μM for ALA-4-ET-1,
>0.5 μM for IRL-1620 and 1–3 nM for BQ-123 [55–57]. In agreement
with these data, we could demonstrate high afﬁnity binding of
BQ-123 to CF expressed ETA-sGFP/MSP1E3D1-NDs (DMPC) com-
plexes, while the other three ligands showed only low afﬁnity. Vice
versa, IRL-1620, ALA-4-ET-1 and ET-3 showed high afﬁnity binding
to CF expressed ETB-sGFP/MSP1E3D1-ND (DMPC) complexes where-
as the apparent KD value of BQ-123 was >1 μM. The ligand afﬁnity of
endothelin receptors is some 10-fold lower in isolated membranes if
compared with intact cells [57]. One known exception is the signiﬁ-
cantly enhanced binding of the peptide agonist IRL-1620 to isolated
membranes containing ETB. It is interesting to note that we can ob-
serve this effect also with the CF produced ETB-sGFP/MSP1E3D1-ND
(DMPC) complexes and an apparent approx. value of some 5 pM
could be obtained.
5. Conclusions
Our results document a new process to produce the two endo-
thelin receptors, ETA and ETB, in a ligand-binding competent form
and to enable the characterization of GPCR signaling properties. The
CF produced GPCR/MSP1E3D1-ND (DMPC) complexes could be di-
rectly analyzed by SPR measurements without previous puriﬁcation
steps. CF expression of the endothelin receptors and subsequent li-
gand binding studies can be completed within two to three days,
thus opening new possibilities for GPCR screening approaches in
natural lipid environments.
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